We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+8.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.74B
AUM Growth
-$74.6M
(-2%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRNX
Crinetics Pharmaceuticals
CRNX
|
+$76.8M |
| 2 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$47.1M |
| 3 |
VRAY
ViewRay, Inc.
VRAY
|
+$35.6M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$21.3M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$65.3M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$64.5M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$57.5M |
| 4 |
Humana
HUM
|
+$36.8M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$35.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.11% |
| 2 | Miscellaneous | 5.71% |
| 3 | Consumer Staples | 0.92% |
| 4 | Financials | 0.17% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ECYT
26
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $43.4M | 1.16% |
2,441,700
+520,000
| +27% | +$8.93M |
|
27
Aldeyra Therapeutics
ALDX
$82.6M
| $42.6M | 1.14% |
3,085,458
| – | – |
|
28
argenx
ARGX
$61.3B
| $42.5M | 1.14% |
560,941
+31,381
| +6% | +$2.78M |
|
29
Intuitive Surgical
ISRG
$133B
| $41.6M | 1.11% |
217,500
-82,500
| -28% | -$14.6M |
|
30
ADMA Biologics
ADMA
$1.93B
| $40.5M | 1.08% |
6,521,102
| – | – |
|
|
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $37.2M | 1% |
990,943
-1,752,704
| -64% | -$64.5M |
|
32
Regenxbio
RGNX
$525M
| $35.5M | 0.95% |
470,672
-396,434
| -46% | -$28.6M |
|
33
uniQure
QURE
$2.99B
| $35.4M | 0.95% |
972,831
-471,797
| -33% | -$17.6M |
|
|
VRAY
34
DELISTED
ViewRay, Inc.
VRAY
| $34.6M | 0.93% |
3,700,000
+3,625,000
| +4,833% | +$35.6M |
|
|
NEPT
35
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $34.5M | 0.92% |
6,351
+227
| +4% | +$1.1M |
|
36
Xencor
XNCR
$1.77B
| $32.3M | 0.86% |
828,095
-240,000
| -22% | -$9.79M |
|
|
NVTA
37
DELISTED
Invitae Corporation
NVTA
| $31.1M | 0.83% |
1,861,100
-160,000
| -8% | -$1.82M |
|
|
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
| $30.4M | 0.81% |
2,742,821
| – | – |
|
|
VBIV
39
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $23.4M | 0.63% |
322,195
| – | – |
|
40
Akebia Therapeutics
AKBA
$250M
| $21.6M | 0.58% |
2,449,521
+234,121
| +11% | +$2.09M |
|
41
Aquestive Therapeutics
AQST
$604M
| $20.1M | 0.54% |
+1,150,000
| New | +$19M |
|
42
Rhythm Pharmaceuticals
RYTM
$6.66B
| $19.4M | 0.52% |
664,186
-136,500
| -17% | -$4.31M |
|
|
FOMX
43
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $17.8M | 0.48% |
3,107,424
+1,990,100
| +178% | +$11.4M |
|
44
Zymeworks
ZYME
$1.86B
| $16.9M | 0.45% |
1,123,890
| – | – |
|
45
iRhythm Holdings
IRTC
$3.69B
| $16M | 0.43% |
168,939
-139,067
| -45% | -$12.1M |
|
46
Establishment Labs
ESTA
$2.13B
| $15.3M | 0.41% |
+635,000
| New | +$16.3M |
|
47
ProQR Therapeutics
PRQR
$260M
| $14.7M | 0.39% |
+761,000
| New | +$8.09M |
|
|
MOTS
48
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $14.3M | 0.38% |
9,368
| – | – |
|
49
LivaNova
LIVN
$4.38B
| $13.8M | 0.37% |
+111,000
| New | +$13.1M |
|
|
SYBX
50
DELISTED
Synlogic
SYBX
| $13.4M | 0.36% |
62,857
| – | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2018 Portfolio in Review
As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Perceptive Advisors withdrew a net $193M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.
- Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
- Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
- Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
- Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
- Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
- Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
- Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.
Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.